Sorafenib Loaded Resealed Erythrocytes for the Treatment of Hepatocellular Carcinoma.

Raj M Desai, Neha Desai, Munira Momin, Lokesh Kumar Bhatt

Recent advances in drug delivery and formulation 2023

filter terms:

This study aims to formulate and characterize sorafenib-loaded resealed erythrocytes (SoRE) and investigate their anticancer activity in a rat model of hepatocellular carcinoma. SoRE were prepared by hypotonic dialysis of red blood cells obtained from Wistar rats using a range of drug-containing dialysis mediums (2-10 mg/ml) and osmosis time (30-240 mins). Optimized SoRE (8 mg/mL and 240 mins) were characterized for size, morphology, stability, entrapment efficiency, in vitro release profiles, and in vivo efficacy evaluations. For efficacy studies, optimized SoRE were intravenously administered to Wistar rats having hepatocellular lesions induced by aflatoxin B and monitored for in vivo antineoplastic activity. The amount of sorafenib entrapped was directly proportional to the drug concentration in the dialysis medium and duration of osmosis; highest for 10 mg/mL and 240 minutes and lowest for 2 mg/mL and 30 minutes, respectively. Optimized SoRE were biconcave with a size of 112.7 nm and zeta potential of -11.95 ± 2.25 mV. Osmotic and turbulence fragility were comparable with native erythrocytes. Drug release follows the first-order pattern. In vivo investigations reveal better anticancer activity of SoRE formulation compared to sorafenib standard preparation. Resealed erythrocytes loaded with sorafenib displayed first-order in vitro release and promising anticancer activity in a rat model of hepatocellular carcinoma. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Citation

Raj M Desai, Neha Desai, Munira Momin, Lokesh Kumar Bhatt. Sorafenib Loaded Resealed Erythrocytes for the Treatment of Hepatocellular Carcinoma. Recent advances in drug delivery and formulation. 2023;17(1):61-70